Restoring the epigenetic landscape of lung microbiome : potential therapeutic approach for chronic respiratory diseases
© 2023. The Author(s)..
BACKGROUND: Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and bronchiectasis, present significant threats to global health. Recent studies have revealed the crucial role of the lung microbiome in the development of these diseases. Pathogens have evolved complex strategies to evade the immune response, with the manipulation of host cellular epigenetic mechanisms playing a pivotal role. There is existing evidence regarding the effects of Pseudomonas on epigenetic modifications and their association with pulmonary diseases. Therefore, this study aims to directly assess the connection between Pseudomonas abundance and chronic respiratory diseases. We hope that our findings will shed light on the molecular mechanisms behind lung pathogen infections.
METHODS: We analyzed data from 366 participants, including individuals with COPD, acute exacerbations of COPD (AECOPD), bronchiectasis, and healthy individuals. Previous studies have given limited attention to the impact of Pseudomonas on these groups and their comparison with healthy individuals. Two independent datasets from different ethnic backgrounds were used for external validation. Each dataset separately analyzed bacteria at the genus level.
RESULTS: The study reveals that Pseudomonas, a bacterium, was consistently found in high concentrations in all chronic lung disease datasets but it was present in very low abundance in the healthy datasets. This suggests that Pseudomonas may influence cellular mechanisms through epigenetics, contributing to the development and progression of chronic respiratory diseases.
CONCLUSIONS: This study emphasizes the importance of understanding the relationship between the lung microbiome, epigenetics, and the onset of chronic pulmonary disease. Enhanced recognition of molecular mechanisms and the impact of the microbiome on cellular functions, along with a better understanding of these concepts, can lead to improved diagnosis and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC pulmonary medicine - 24(2024), 1 vom: 02. Jan., Seite 2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KavianFar, Azadeh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic respiratory diseases |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 06.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12890-023-02789-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366575139 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366575139 | ||
| 003 | DE-627 | ||
| 005 | 20240108142623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12890-023-02789-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1250.xml |
| 035 | |a (DE-627)NLM366575139 | ||
| 035 | |a (NLM)38166878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a KavianFar, Azadeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Restoring the epigenetic landscape of lung microbiome |b potential therapeutic approach for chronic respiratory diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 06.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and bronchiectasis, present significant threats to global health. Recent studies have revealed the crucial role of the lung microbiome in the development of these diseases. Pathogens have evolved complex strategies to evade the immune response, with the manipulation of host cellular epigenetic mechanisms playing a pivotal role. There is existing evidence regarding the effects of Pseudomonas on epigenetic modifications and their association with pulmonary diseases. Therefore, this study aims to directly assess the connection between Pseudomonas abundance and chronic respiratory diseases. We hope that our findings will shed light on the molecular mechanisms behind lung pathogen infections | ||
| 520 | |a METHODS: We analyzed data from 366 participants, including individuals with COPD, acute exacerbations of COPD (AECOPD), bronchiectasis, and healthy individuals. Previous studies have given limited attention to the impact of Pseudomonas on these groups and their comparison with healthy individuals. Two independent datasets from different ethnic backgrounds were used for external validation. Each dataset separately analyzed bacteria at the genus level | ||
| 520 | |a RESULTS: The study reveals that Pseudomonas, a bacterium, was consistently found in high concentrations in all chronic lung disease datasets but it was present in very low abundance in the healthy datasets. This suggests that Pseudomonas may influence cellular mechanisms through epigenetics, contributing to the development and progression of chronic respiratory diseases | ||
| 520 | |a CONCLUSIONS: This study emphasizes the importance of understanding the relationship between the lung microbiome, epigenetics, and the onset of chronic pulmonary disease. Enhanced recognition of molecular mechanisms and the impact of the microbiome on cellular functions, along with a better understanding of these concepts, can lead to improved diagnosis and treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic respiratory diseases | |
| 650 | 4 | |a Epigenetic | |
| 650 | 4 | |a Lung microbiome | |
| 650 | 4 | |a Pseudomonas | |
| 700 | 1 | |a Taherkhani, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Salimi, Mahdieh |e verfasserin |4 aut | |
| 700 | 1 | |a Lanjanian, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Masoudi-Nejad, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 24(2024), 1 vom: 02. Jan., Seite 2 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:02 |g month:01 |g pages:2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-023-02789-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 02 |c 01 |h 2 | ||